Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredric J Cohen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nature Reviews. Drug Discovery|March 15, 2006
Entry order as a consideration for innovation strategiesFredric J Cohen
Discovery Medicine|August 14, 2010
Macro trends in pharmaceutical innovationFredric J Cohen
Nature Reviews. Drug Discovery|February 3, 2005
Macro trends in pharmaceutical innovationFredric J Cohen
Diabetes Care|May 27, 2003
Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetesFredric J Cohen, Cheryl A Neslusan, Jonathan E Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxideTakashi Kumagai, Takayuki Ikezoe, Dorina Gui, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nature Reviews. Drug Discovery|March 15, 2006
Entry order as a consideration for innovation strategiesFredric J Cohen
Discovery Medicine|August 14, 2010
Macro trends in pharmaceutical innovationFredric J Cohen
Nature Reviews. Drug Discovery|February 3, 2005
Macro trends in pharmaceutical innovationFredric J Cohen
Diabetes Care|May 27, 2003
Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetesFredric J Cohen, Cheryl A Neslusan, Jonathan E Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxideTakashi Kumagai, Takayuki Ikezoe, Dorina Gui, et al.
Pageof 1